AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Anidulafungin In Treatment Of Candidemia In Asian Subjects

Phase 3

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2007-10-01

Last Posted Date: 2010-03-09

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00537329

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Phase 1

Completed

Conditions: Generalized Anxiety Disorder

First Posted Date: 2007-10-01

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00537615

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Fesoterodine Flexible Dose Study

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2007-09-27

Last Posted Date: 2009-09-15

Lead Sponsor: Pfizer

Target Recruit Count: 896

Registration Number: NCT00536484

Locations: 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States

ACTiF- Assessment of Closed Tibial Fractures

Phase 2

Completed

Conditions: Tibial Fractures

Interventions: Drug: CP-533, 536
Drug: Placebo
Procedure: Standard of Care
Drug: CP-533,536

First Posted Date: 2007-09-21

Last Posted Date: 2012-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 276

Registration Number: NCT00533377

Locations: 🇹🇷
Pfizer Investigational Site, Izmir, Turkey

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo capsules
Drug: PF-03654746

First Posted Date: 2007-09-19

Last Posted Date: 2016-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00531752

Locations: 🇺🇸
Bay Area Research Institute, Lafayette, California, United States
🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸
New York University School of Medicine, New York, New York, United States

and more 3 locations